Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar & Mohsen Heidary. (2022) Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Review of Anti-infective Therapy 20:8, pages 1135-1147.
Read now
Read now
Diana Canetti & Vincenzo Spagnuolo. (2021) An evaluation of cabotegravir for HIV treatment and prevention. Expert Opinion on Pharmacotherapy 22:4, pages 403-414.
Read now
Read now
Cristina Fernandez & Clare L van Halsema. (2019) Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV/AIDS - Research and Palliative Care 11, pages 179-192.
Read now
Read now
Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, Hans Jaeger, Viviam Canon, David Dorey, Sandy Griffith, Joseph Mrus, William Spreen & David Margolis. (2019) Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Research & Clinical Practice 20:4-5, pages 111-122.
Read now
Read now
Laura Benítez-Gutiérrez, Vicente Soriano, Silvia Requena, Ana Arias, Pablo Barreiro & Carmen de Mendoza. (2018) Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Review of Clinical Pharmacology 11:5, pages 507-517.
Read now
Read now
Tristan D. McPherson, Magdalena E. Sobieszczyk & Martin Markowitz. (2018) Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opinion on Investigational Drugs 27:4, pages 413-420.
Read now
Read now
Said A. Hassounah & Thibault Mesplède. (2018) Where are we with injectables against HIV infection and what are the remaining challenges?. Expert Review of Anti-infective Therapy 16:2, pages 143-152.
Read now
Read now
Yingshan Han, Thibault Mesplède & Mark A. Wainberg. (2017) Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs 26:11, pages 1207-1213.
Read now
Read now
Ayşe Elif Özdener, Tae Eun Park, Julie Kalabalik & Rachna Gupta. (2017) The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. Expert Review of Anti-infective Therapy 15:5, pages 467-481.
Read now
Read now
Thomas Whitfield, Adele Torkington & Clare van Halsema. (2016) Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV/AIDS - Research and Palliative Care 8, pages 157-164.
Read now
Read now
Melinda J. Reese, Gary D. Bowers, Joan E. Humphreys, Elizabeth P. Gould, Susan L. Ford, Lindsey O. Webster & Joseph W. Polli. (2016) Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica 46:5, pages 445-456.
Read now
Read now
Gary David Bowers, Amanda Culp, Melinda J. Reese, Glenn Tabolt, Lee Moss, Stephen Piscitelli, Phuong Huynh, David Wagner, Susan L. Ford, Elizabeth P. Gould, Rennan Pan, Yu Lou, David A. Margolis & William R. Spreen. (2016) Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica 46:2, pages 147-162.
Read now
Read now
Tae Eun Park, Abdilahi Mohamed, Julie Kalabalik & Roopali Sharma. (2015) Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Review of Anti-infective Therapy 13:10, pages 1195-1212.
Read now
Read now
Articles from other publishers (77)
Christina G. Rivera, John D. Zeuli, Bradley L. Smith, Tanner M. Johnson, Ramona Bhatia, Ashley O. Otto & Zelalem Temesgen. (2023) HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic. Drugs.
Crossref
Crossref
Mark A Marzinke, Brett Hanscom, Zhe Wang, Steven A Safren, Christina Psaros, Deborah Donnell, Paul A Richardson, Philip Sullivan, Susan H Eshleman, Andrea Jennings, Kailazarid Gomez Feliciano, Emilia Jalil, Carolina Coutinho, Nadir Cardozo, Bernardo Maia, Taimur Khan, Yashna Singh, Keren Middelkoop, Julie Franks, Javier Valencia, Naiymah Sanchez, Jonathan Lucas, James F Rooney, Alex R Rinehart, Susan Ford, Adeola Adeyeye, Myron S Cohen, Marybeth McCauley, Raphael J Landovitz, Beatriz Grinsztejn, Suwat Chariyalertsak, Chaiwat Ungsedhapand, Nittaya Phanuphak, Tran Viet Ha, María Inés Figueroa, Marcelo H. Losso, Esper G. Kallas, José Valdez Madruga, Breno Riegel Santos, Beatriz Grinsztejn, Juan Carlos Hinojosa Boyer, Milagros Erika Matta Aguirre, Jorge A Gallardo-Cartagena, Javier Valencia, Yvett Pinedo Ramirez, Keren Middelkoop, Paul Goepfert, Sybil Hosek, Albert Liu, Jessica Justman, Christopher Hurt, Daniel Reirden, Carl Fichtenbaum, Christopher Hall, Kenneth Mayer, Manya Magnus, Cornelius van Dam, Julie Franks, Colleen Kelley, Roberto C. Arduino, Anne Rompalo, Shobha Swaminathan, Sue Ellen Abdalian, Hong Van Tieu, Jose Bazan, Ian Frank, Carlos del Rio, Aditya Gaur, Raphael J. Landovitz, Jesse Clark, Richard Novak, Rachel Presti & Roy (Trip) Gulick. (2023) Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. The Lancet HIV.
Crossref
Crossref
Damien Bonnard, Erwann Le Rouzic, Matthew R. Singer, Zhe Yu, Frédéric Le Strat, Claire Batisse, Julien Batisse, Céline Amadori, Sophie Chasset, Valerie E. Pye, Stéphane Emiliani, Benoit Ledoussal, Marc Ruff, François Moreau, Peter Cherepanov & Richard Benarous. (2023) Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase. Antimicrobial Agents and Chemotherapy 67:7.
Crossref
Crossref
Ashley R. Johnson, Jeanine E. Ballard, Andrew Leithead, Corin Miller, Fried Faassen, Xiaowei Zang, Rebecca Nofsinger & Angela M. Wagner. (2023) A Retrospective Analysis of Preclinical and Clinical Pharmacokinetics from Administration of Long-Acting Aqueous Suspensions. Pharmaceutical Research 40:7, pages 1641-1656.
Crossref
Crossref
Ethel D. Weld, Teresa L. Parsons, Ryann Gollings, Marybeth McCauley, Beatriz Grinsztejn, Raphael J. Landovitz & Mark A. Marzinke. (2023) Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. Journal of Pharmaceutical and Biomedical Analysis 228, pages 115307.
Crossref
Crossref
Mark A. Marzinke, Jessica M. Fogel, Zhe Wang, Estelle Piwowar-Manning, Ryan Kofron, Amber Moser, Pradip Bhandari, Ryann Gollings, Lane R. Bushman, Lei Weng, Elias K. Halvas, John Mellors, Peter L. Anderson, Deborah Persaud, Craig W. Hendrix, Marybeth McCauley, Alex R. Rinehart, Marty St Clair, Susan L. Ford, James F. Rooney, Adeola Adeyeye, Suwat Chariyalertsak, Kenneth Mayer, Roberto C. Arduino, Myron S. Cohen, Beatriz Grinsztejn, Brett Hanscom, Raphael J. Landovitz & Susan H. Eshleman. (2023) Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrobial Agents and Chemotherapy 67:4.
Crossref
Crossref
Purnima Rawat, Syed Sarim Imam & Sharad Gupta. (2022) Formulation of Cabotegravir Loaded Gold Nanoparticles: Optimization, Characterization to In-Vitro Cytotoxicity Study. Journal of Cluster Science 34:2, pages 893-905.
Crossref
Crossref
Erika AraujoIan M. BellAlexander Burckle, Dennis C. Koester, James R. Manning, Richard D. CaldwellGeorgette Castanedo, Samantha A. Green, Mingshuo Zeng, Laurent DebienT. G. Murali DharNatalie Holmberg-Douglas, Eric R. Welin, J. Robert MerrittKevin M. PeeseDenise C. GrünenfelderJulian C. Lo. 2022. 2022 Medicinal Chemistry Reviews. 2022 Medicinal Chemistry Reviews
587
731
.
Clémence Richetta, Nhat Tu & Olivier Delelis. (2022) Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance. Viruses 14:12, pages 2591.
Crossref
Crossref
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy P. Moore, Ciara S. Seal, Amy G. Cutrell, Ronald D. D'Amico, Paul D. Benn, Raphael J. Landovitz, Mark A. Marzinke, William R. Spreen & Susan L. Ford. (2022) Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects. British Journal of Clinical Pharmacology 88:10, pages 4607-4622.
Crossref
Crossref
Christoph D Spinner, Franco Felizarta, Giuliano Rizzardini, Patrick Philibert, Essack Mitha, Pere Domingo, Christoph J Stephan, Michelle DeGrosky, Veronica Bainbridge, Joyce Zhan, Teodora Pene Dumitrescu, Jerry L Jeffrey, Jianfeng Xu, Fiona Halliday, Jianjun Gan, Mark Johnson, Martin Gartland, Samit R Joshi & Max Lataillade. (2022) Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. Clinical Infectious Diseases 75:5, pages 786-794.
Crossref
Crossref
Haneesha Mohan, Kieran Atkinson, Birgit Watson, Chanson J. Brumme & Lena Serghides. (2022) A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model. Pharmaceutics 14:9, pages 1761.
Crossref
Crossref
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, Gordon Chau, Vanessa Cummings, Yaw Agyei, Paul Richardson, Philip Sullivan, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Ryan Kofron, Craig W Hendrix, Peter L Anderson, Jennifer Farrior, John Mellors, Adeola Adeyeye, Alex Rinehart, Marty St Clair, Susan Ford, James F Rooney, Carrie-Anne Mathew, Portia Hunidzarira, Elizabeth Spooner, Juliet Mpendo, Gonasagrie Nair, Myron S Cohen, James P Hughes, Mina Hosseinipour, Brett Hanscom, Sinead Delany-Moretlwe & Mark A Marzinke. (2022) Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. The Journal of Infectious Diseases 225:10, pages 1741-1749.
Crossref
Crossref
Jafar Sadik Shaik, Ethel D. Weld, Stacey Edick, Edward Fuchs, Sharon Riddler, Mark A. Marzinke, Ronald D'Amico, Kalpana Bakshi, Yu Lou, Craig Hendrix, Kelong Han, Susan L. Ford, David Margolis, William Spreen & Parul Patel. (2021) Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis. British Journal of Clinical Pharmacology 88:4, pages 1667-1678.
Crossref
Crossref
Olumuyiwa E Ariyo & Christopher E Jones. (2022) Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review. Journal of Clinical Virology 146, pages 105032.
Crossref
Crossref
Nagsen Gautam, JoEllyn M. McMillan, Devendra Kumar, Aditya N. Bade, Qiaoyu Pan, Tanmay A. Kulkarni, Wenkuan Li, Brady Sillman, Nathan A. Smith, Bhagya L. Dyavar Shetty, Adam Szlachetka, Benson J. Edagwa, Howard E. Gendelman & Yazen Alnouti. (2021) Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nature Communications 12:1.
Crossref
Crossref
Panita Maturavongsadit, Gayane Paravyan, Martina Kovarova, J. Victor Garcia & S. Rahima Benhabbour. (2021) A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery. International Journal of Pharmaceutics: X 3, pages 100068.
Crossref
Crossref
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, Estelle Piwowar-Manning, Maoji Li, Lei Weng, Marybeth McCauley, Vanessa Cummings, Shahnaz Ahmed, Casey D Haines, Lane R Bushman, Christos Petropoulos, Deborah Persaud, Adeola Adeyeye, Ryan Kofron, Alex Rinehart, Marty St Clair, James F Rooney, Daniel Pryluka, Lara Coelho, Aditya Gaur, Keren Middelkoop, Nittaya Phanuphak, Myron S Cohen, Craig W Hendrix, Peter Anderson, Brett Hanscom, Deborah Donnell, Raphael J Landovitz & Susan H Eshleman. (2021) Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. The Journal of Infectious Diseases 224:9, pages 1581-1592.
Crossref
Crossref
Jennifer A Smith, Geoffrey P Garnett & Timothy B Hallett. (2021) The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study. The Journal of Infectious Diseases 224:7, pages 1179-1186.
Crossref
Crossref
Zach W. Howe, Sarah Norman, Abbie F. Lueken, Emily Huesgen, Eric K. Farmer, Kaitlyn Jarrell, Joscelyn E. Mathis, Kyle W. Bonham & Julie Hahn. (2021) Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:8, pages 686-699.
Crossref
Crossref
Daryl Hodge, David J. Back, Sara Gibbons, Saye H. Khoo & Catia Marzolini. (2021) Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics 60:7, pages 835-853.
Crossref
Crossref
Kathleen D. Engelman & Alan N. Engelman. (2021) Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. Biochemistry 60:22, pages 1731-1740.
Crossref
Crossref
Nokuzola Mbhele, Benjamin Chimukangara & Michelle Gordon. (2021) HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents 57:5, pages 106343.
Crossref
Crossref
Herana Kamal Seneviratne, Allyson N. Hamlin, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y. Liu, Irene Kuo, Mina C. Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Adeola Adeyeye, Alex R. Rinehart, Marybeth McCauley, Joseph S. Eron, Myron S. Cohen, Raphael J. Landovitz, Craig W. Hendrix & Namandjé N. Bumpus. (2021) Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. ACS Pharmacology & Translational Science 4:1, pages 226-239.
Crossref
Crossref
Dipu Karunakaran, Solange M. Simpson, Jonathan T. Su, Ewa Bryndza-Tfaily, Thomas J. Hope, Ronald Veazey, Georgina Dobek, Jiang Qiu, David Watrous, Samuel Sung, Jorge E. Chacon & Patrick F. Kiser. (2021) Design and Testing of a Cabotegravir Implant for HIV Prevention. Journal of Controlled Release 330, pages 658-668.
Crossref
Crossref
Kimberly K. Scarsi & Susan Swindells. (2021) The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. Journal of the International Association of Providers of AIDS Care (JIAPAC) 20, pages 232595822110090.
Crossref
Crossref
Lucile Pencolé, Minh P. Lê, Florian Bouchet-Crivat, Dominique Duro, Gilles Peytavin & Laurent Mandelbrot. (2020) Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model. AIDS 34:14, pages 2145-2149.
Crossref
Crossref
Kimberly K. Scarsi, Joshua P. Havens, Anthony T. Podany, Sean N. Avedissian & Courtney V. Fletcher. (2020) HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs 80:16, pages 1649-1676.
Crossref
Crossref
Anthony T. Podany, Kimberly K. Scarsi, Michelle M. Pham & Courtney V. Fletcher. (2020) Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. Clinical Pharmacokinetics 59:9, pages 1085-1107.
Crossref
Crossref
A. Markham. (2020) Cabotegravir Plus Rilpivirine: First Approval. Drugs 80:9, pages 915-922.
Crossref
Crossref
Aadia I. Rana, Jose R. Castillo-Mancilla, Karen T. Tashima & Raphael L. Landovitz. (2020) Advances in Long-Acting Agents for the Treatment of HIV Infection. Drugs 80:6, pages 535-545.
Crossref
Crossref
Scott L Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome Devente, Christopher Bettacchi, Yu Lou, Susan Ford, Kenneth Sutton, Jafar Sadik Shaik, Herta Crauwels, Ronald D’Amico & Parul Patel. (2020) Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. Journal of Antimicrobial Chemotherapy 75:3, pages 648-655.
Crossref
Crossref
Meredith E. Clement, Ryan Kofron & Raphael J. Landovitz. (2020) Long-acting injectable cabotegravir for the prevention of HIV infection. Current Opinion in HIV and AIDS 15:1, pages 19-26.
Crossref
Crossref
Fernanda P. Pons-Faudoa, Antons Sizovs, Nicola Di Trani, Jesus Paez-Mayorga, Giacomo Bruno, Jessica Rhudy, Madhuri Manohar, Kevin Gwenden, Cecilia Martini, Corrine Ying Xuan Chua, Greta Varchi, Mark A. Marzinke & Alessandro Grattoni. (2019) 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. Journal of Controlled Release 306, pages 89-96.
Crossref
Crossref
Ridhi Parasrampuria, Susan L. Ford, Yu Lou, Caifeng Fu, Kalpana K. Bakshi, Allan R. Tenorio, Christine Trezza, William R. Spreen & Parul Patel. (2019) A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants. Clinical Pharmacology in Drug Development 8:5, pages 674-681.
Crossref
Crossref
Jafar Sadik B. Shaik, Susan L. Ford, Yu Lou, Zhiping Zhang, Kalpana K. Bakshi, Allan R. Tenorio, Christine Trezza, William R. Spreen & Parul Patel. (2019) A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls. Clinical Pharmacology in Drug Development 8:5, pages 664-673.
Crossref
Crossref
Dario Cattaneo & Cristina Gervasoni. (2018) Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 44:3, pages 319-327.
Crossref
Crossref
Roy M. GulickCharles Flexner. (2019) Long-Acting HIV Drugs for Treatment and Prevention. Annual Review of Medicine 70:1, pages 137-150.
Crossref
Crossref
Charles Flexner. (2018) Modern Human Immunodeficiency Virus Therapy: Progress and Prospects. Clinical Pharmacology & Therapeutics 105:1, pages 61-70.
Crossref
Crossref
Eungi Choi, Jayapal Reddy Mallareddy, Dai Lu & Srikanth Kolluru. (2018) Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Science OA 4:9, pages FSO338.
Crossref
Crossref
Robert A. Smith, Vincent H. Wu, Christopher G. Zavala, Dana N. Raugi, Selly Ba, Moussa Seydi & Geoffrey S. Gottlieb. (2018)
In Vitro
Antiviral Activity of Cabotegravir against HIV-2
. Antimicrobial Agents and Chemotherapy 62:10.
Crossref
Crossref
Burcin Yavuz, Jessica L. Morgan, Laura Showalter, Katti R. Horng, Satya Dandekar, Carolina Herrera, Patricia LiWang & David L. Kaplan. (2018) Pharmaceutical Approaches to HIV Treatment and Prevention. Advanced Therapeutics 1:6, pages 1800054.
Crossref
Crossref
Hans-Jürgen Stellbrink & Christian Hoffmann. (2018) Cabotegravir. Current Opinion in HIV and AIDS 13:4, pages 334-340.
Crossref
Crossref
Joseph S. Redman, J. Nicholas Francis, Robert Marquardt, Damon Papac, Alan L. Mueller, Debra M. Eckert, Brett D. Welch & Michael S. Kay. (2018)
Pharmacokinetic and Chemical Synthesis Optimization of a Potent
d
-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery
. Molecular Pharmaceutics 15:3, pages 1169-1179.
Crossref
Crossref
Tian Zhou, Hang Su, Prasanta Dash, Zhiyi Lin, Bhagya Laxmi Dyavar Shetty, Ted Kocher, Adam Szlachetka, Benjamin Lamberty, Howard S. Fox, Larisa Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, R. Lee Mosley, Yazen Alnouti, Benson Edagwa & Howard E. Gendelman. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, pages 53-65.
Crossref
Crossref
Paolo Maggi, Antonio Di Biagio, Stefano Rusconi, Stefania Cicalini, Maurizio D’Abbraccio, Gabriella d’Ettorre, Canio Martinelli, Giuseppe Nunnari, Laura Sighinolfi, Vincenzo Spagnuolo & Nicola Squillace. (2017) Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infectious Diseases 17:1.
Crossref
Crossref
William R. Lykins, Ellen Luecke, Daniel Johengen, Ariane van der Straten & Tejal A. Desai. (2017) Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Delivery and Translational Research 7:6, pages 805-816.
Crossref
Crossref
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Daniel Podzamczer, Thomas Lutz, Jonathan B Angel, Gary J Richmond, Bonaventura Clotet, Felix Gutierrez, Louis Sloan, Marty St Clair, Miranda Murray, Susan L Ford, Joseph Mrus, Parul Patel, Herta Crauwels, Sandy K Griffith, Kenneth C Sutton, David Dorey, Kimberly Y Smith, Peter E Williams & William R Spreen. (2017) Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. The Lancet 390:10101, pages 1499-1510.
Crossref
Crossref
Martin Markowitz, Ian Frank, Robert M Grant, Kenneth H Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E Sobieszczyk, Joel E Gallant, Hong Van Tieu, Winkler Weinberg, David A Margolis, Krischan J Hudson, Britt S Stancil, Susan L Ford, Parul Patel, Elizabeth Gould, Alex R Rinehart, Kimberly Y Smith & William R Spreen. (2017) Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet HIV 4:8, pages e331-e340.
Crossref
Crossref
Amesika N Nyaku, Sean G Kelly & Babafemi O Taiwo. (2017) Long-Acting Antiretrovirals: Where Are We now?. Current HIV/AIDS Reports 14:2, pages 63-71.
Crossref
Crossref
Chasity D. Andrews, Leslie St. Bernard, Amanda Yee Poon, Hiroshi Mohri, Natanya Gettie, William R. Spreen, Agegnehu Gettie, Kasi Russell-Lodrigue, James Blanchard, Zhi Hong, David D. Ho & Martin Markowitz. (2017) Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS 31:4, pages 461-467.
Crossref
Crossref
Yu Lou, Ann M. Buchanan, Shuguang Chen, Susan L. Ford, Elizabeth Gould, David Margolis, William R. Spreen & Parul Patel. (2016) Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects. Clinical Pharmacology in Drug Development 5:6, pages 509-516.
Crossref
Crossref
Marco Siccardi, Phillip Martin, Darren Smith, Paul Curley, Tom McDonald, Marco Giardiello, Neill Liptrott, Steve Rannard & Andrew Owen. (2016) Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. Journal of Interdisciplinary Nanomedicine 1:3, pages 110-123.
Crossref
Crossref
Y Xu, YF Li, D Zhang, M Dockendorf, E Tetteh, ML Rizk, JA Grobler, M‐T Lai, J Gobburu & W Ankrom. (2016) Characterizing Class‐Specific Exposure‐Viral Load Suppression Response of HIV Antiretrovirals Using A Model‐Based Meta‐Analysis. Clinical and Translational Science 9:4, pages 192-200.
Crossref
Crossref
Tomas Cihlar & Marshall Fordyce. (2016) Current status and prospects of HIV treatment. Current Opinion in Virology 18, pages 50-56.
Crossref
Crossref
Richard Elion & Megan Coleman. (2016) The preexposure prophylaxis revolution. Current Opinion in HIV and AIDS 11:1, pages 67-73.
Crossref
Crossref
Raphael J. Landovitz, Ryan Kofron & Marybeth McCauley. (2016) The promise and pitfalls of long-acting injectable agents for HIV prevention. Current Opinion in HIV and AIDS 11:1, pages 122-128.
Crossref
Crossref
Isabelle Malet, Eloise Thierry, Marc Wirden, Samuel Lebourgeois, Frédéric Subra, Christine Katlama, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcelin & Olivier Delelis. (2015) Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. Journal of Antimicrobial Chemotherapy 70:10, pages 2870-2880.
Crossref
Crossref
David A Margolis, Cynthia C Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Joseph J Eron, Sandy K Griffith, Marty H St Clair, Marita C Stevens, Peter E Williams, Susan L Ford, Britt S Stancil, Melinda M Bomar, Krischan J Hudson, Kimberly Y Smith & William R Spreen. (2015) Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases 15:10, pages 1145-1155.
Crossref
Crossref
Carlos F Cáceres, Kenneth H Mayer, Rachel Baggaley & Kevin R O’Reilly. (2015) PrEP Implementation Science: State-of-the-Art and Research Agenda. Journal of the International AIDS Society 18, pages 20527.
Crossref
Crossref
Catherine Hankins, Ruth Macklin & Mitchell Warren. (2015) Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. Journal of the International AIDS Society 18, pages 19973.
Crossref
Crossref
David A. Margolis & Marta Boffito. (2015) Long-acting antiviral agents for HIV treatment. Current Opinion in HIV and AIDS 10:4, pages 246-252.
Crossref
Crossref
Christine Trezza, Susan L. Ford, William Spreen, Rennan Pan & Stephen Piscitelli. (2015) Formulation and pharmacology of long-acting cabotegravir. Current Opinion in HIV and AIDS 10:4, pages 239-245.
Crossref
Crossref
Martin Markowitz & Kathrine Meyers. (2015) Extending access with long-acting antiretroviral therapy. Current Opinion in HIV and AIDS 10:4, pages 216-218.
Crossref
Crossref
Chasity D. Andrews & Walid Heneine. (2015) Cabotegravir long-acting for HIV-1 prevention. Current Opinion in HIV and AIDS 10:4, pages 258-263.
Crossref
Crossref
Lee M Tatham, Steven P Rannard & Andrew Owen. (2015) Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Therapeutic Delivery 6:4, pages 469-490.
Crossref
Crossref
Eric L. Ross, Milton C. Weinstein, Bruce R. Schackman, Paul E. Sax, A. David Paltiel, Rochelle P. Walensky, Kenneth A. Freedberg & Elena Losina. (2015) The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 60:7, pages 1102-1110.
Crossref
Crossref
Chasity D. AndrewsYun Lan YuehWilliam R. SpreenLeslie St. BernardMar Boente-CarreraKristina RodriguezAgegnehu GettieKasi Russell-LodrigueJames BlanchardSusan FordHiroshi MohriCecilia Cheng-MayerZhi HongDavid D. HoMartin Markowitz. (2015) A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Science Translational Medicine 7:270.
Crossref
Crossref
Tomokazu Yoshinaga, Masanori Kobayashi, Takahiro Seki, Shigeru Miki, Chiaki Wakasa-Morimoto, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark R. Underwood, Edward P. Garvey, Akihiko Sato & Tamio Fujiwara. (2015) Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection. Antimicrobial Agents and Chemotherapy 59:1, pages 397-406.
Crossref
Crossref
Fiona L. Hatton, Lee M. Tatham, Louise R. Tidbury, Pierre Chambon, Tao He, Andrew Owen & Steven P. Rannard. (2015) Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. Chemical Science 6:1, pages 326-334.
Crossref
Crossref
Tom O. McDonald, Marco Siccardi, Darren Moss, Neill Liptrott, Marco Giardiello, Steve Rannard & Andrew Owen. 2015. Nanoengineering. Nanoengineering
173
223
.
William Spreen, Peter Williams, David Margolis, Susan L. Ford, Herta Crauwels, Yu Lou, Elizabeth Gould, Marita Stevens & Stephen Piscitelli. (2014) Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:5, pages 487-492.
Crossref
Crossref
William Spreen, Susan L. Ford, Shuguang Chen, David Wilfret, David Margolis, Elizabeth Gould & Stephen Piscitelli. (2014) GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:5, pages 481-486.
Crossref
Crossref
Amanda D. Castel, Manya Magnus & Alan E. Greenberg. (2014) Pre-exposure Prophylaxis for Human Immunodeficiency Virus. Infectious Disease Clinics of North America 28:4, pages 563-583.
Crossref
Crossref
Dorothy E. Dow & John A. Bartlett. (2014) Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infectious Diseases and Therapy 3:2, pages 83-102.
Crossref
Crossref
Sean E. Collins, Philip M. Grant, Eugene T. Richardson & Andrew R. Zolopa. (2014) Integrating Integrase Inhibitors Into an Antiretroviral Regimen. Current Treatment Options in Infectious Diseases 6:2, pages 144-158.
Crossref
Crossref
Chasity D. AndrewsWilliam R. SpreenHiroshi MohriLee MossSusan FordAgegnehu GettieKasi Russell-LodrigueRudolf P. BohmCecilia Cheng-MayerZhi HongMartin MarkowitzDavid D. Ho. (2014) Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. Science 343:6175, pages 1151-1154.
Crossref
Crossref